progression free survival

Showing 1 posts of 1 posts found.

sample

Breast cancer trial stopped after meeting primary endpoint early

May 18, 2016
Research and Development LEE011, Novartis, breast cancer, progression free survival, ribociclib

A Phase III trial evaluating LEE011 (ribociclib), developed by Novartis, has been stopped early after a recommendation from an independent …

The Gateway to Local Adoption Series

Latest content